ANL on Nasdaq
Adlai Nortye Group Ltd.
Price unavailable
Last updated Oct 16, 2026.
Overview
-$51.9MNet income, fiscal 20242
Compare with PROCYON CORP, InMed Pharmaceuticals Inc. or Ensysce Biosciences, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2023
Where the money goes
Where each dollar of revenue went, fiscal 2023
- Other costs100¢$5.0M
Out of $5.0M in revenue.2 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| REVENUE | $5.0M | ||
| Other operating income, net | $396.0K | $1.9M | $890.0K |
| General and administrative expense | -$8.3M | -$10.0M | -$15.3M |
| Research and development expenses | -$32.8M | -$44.9M | -$58.2M |
| Total operating loss | -$35.7M | -$52.9M | -$72.6M |
| Other income and gains | $1.5M | $3.0M | $3.3M |
| Other (expenses)/income | $228.0K | -$42.0K | -$80.0K |
| Investment income | $1.0K | $62.0K | |
| Share of loss of investments accounted for using the equity method | -$3.0K | -$4.0K | |
| Fair value loss on financial liabilities at FVTPL | -$39.2M | ||
| Finance costs | -$1.5M | -$1.9M | -$791.0K |
| LOSS BEFORE TAX | -$35.5M | -$51.9M | -$109.2M |
| LOSS FOR THE YEAR | -$35.5M | -$51.9M | -$109.2M |
| Ordinary Equity Holders of the Parent | -$35.5M | -$51.9M | -$109.2M |
| Exchange differences on translation of the financial statements of subsidiaries | $189.0K | -$294.0K | -$82.0K |
| Other comprehensive (loss)/income for the year, net of tax | $189.0K | -$294.0K | -$82.0K |
| TOTAL COMPREHENSIVE LOSS FOR THE YEAR | -$35.3M | -$52.2M | -$109.3M |
| Ordinary Equity Holders of the Parent | -$35.3M | -$52.2M | -$109.3M |
| Basic loss for the year (in Dollars per share) | -$0.37 | -$0.54 | -$2.52 |
| Diluted loss for the year (in Dollars per share) | -$0.37 | -$0.54 | -$2.52 |
| Weighted average common shares outstanding, basic (in Shares) | 95.9M shares | 95.8M shares | 43.3M shares |
| Weighted average common shares outstanding, diluted (in Shares) | 95.9M shares | 95.8M shares | 43.3M shares |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $8.1M | $60.9M | $91.5M |
| Financial assets at FVTPL | $7.0K | ||
| Prepayments, other receivables and other assets | $3.1M | $3.1M | |
| Other receivables -related party | $15.0K | $14.0K | |
| Restricted cash | $15.7M | ||
| Total current assets | $26.9M | $64.1M | |
| Property, plant and equipment | $1.2M | $1.7M | $2.6M |
| Right-of-use assets | $1.8M | $962.0K | $1.2M |
| Other intangible assets | $19.0K | $40.0K | |
| Other receivables and other assets | $253.0K | $304.0K | |
| Long-term equity investments | $4.2M | $4.2M | |
| Total non-current assets | $7.5M | $7.2M | |
| Total assets | $20.0K | $71.3M | |
| Trade payables | $12.6M | $10.1M | |
| Contract Liabilities | $5.0M | ||
| Other payables and accruals | $3.7M | $3.4M | |
| Interest-bearing bank borrowings | $24.6M | $26.3M | |
| Lease liabilities | $667.0K | $471.0K | |
| Total current liabilities | $41.6M | $45.4M | |
| Lease liabilities | $1.1M | $425.0K | |
| Total non-current liabilities | $1.1M | $425.0K | |
| Total liabilities | $42.8M | $45.8M | |
| Share premium | $439.3M | $439.0M | |
| Share based payments reserve | $21.6M | $20.3M | |
| Foreign exchange fluctuation reserve | -$4.3M | -$4.5M | |
| Accumulated deficit | -$464.8M | -$429.3M | $4.4M |
| Total shareholders equity/(deficit) | -$8.3M | $25.5M | $75.0M |
| Total liabilities and shareholders equity | $34.4M | $71.3M | |
| Ordinary shares, par value (in Dollars per share) | $0.00 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net Loss | -$35.5M | -$51.9M | -$109.2M |
| Finance costs | $1.5M | $1.9M | $791.0K |
| Investment income | -$1.0K | -$62.0K | |
| Investment loss from long term equity investment | $3.0K | $4.0K | |
| Interest income from investment at amortized cost | -$116.0K | -$701.0K | |
| Fair value loss on financial liabilities at FVTPL | $39.2M | ||
| Loss on disposal of items of property, plant and equipment | $23.0K | ||
| Depreciation of property, plant and equipment | $741.0K | $982.0K | $1.2M |
| Amortization of intangible assets | $22.0K | $22.0K | $25.0K |
| Depreciation of right-of-use assets | $650.0K | $866.0K | $984.0K |
| Equity-settled share-based payment expenses | $1.5M | $2.5M | $4.3M |
| (Increase)/Decrease in prepayments, other receivables and other assets | $165.0K | -$460.0K | -$436.0K |
| (Increase)/Decrease in non-current assets | $51.0K | -$22.0K | $45.0K |
| Increase/(Decrease) in trade payables | $2.5M | -$4.2M | $1.3M |
| Increase/(Decrease) in other payables and accruals | $7.0K | -$856.0K | $263.0K |
| Increase/(Decrease) in contract liabilities | -$5.0M | $5.0M | |
| Net cash flows used in operating activities | -$33.5M | -$51.8M | -$56.7M |
| Purchases of property, plant and equipment | -$187.0K | -$170.0K | -$200.0K |
| Proceeds from disposal of items of property, plant and equipment | $33.0K | $1.0K | |
| Purchases of financial assets at FVTPL | -$5.0M | -$7.0K | |
| Disposal of financial assets at FVTPL | $5.0M | $21.0M | |
| Purchases of investments at amortized cost | -$15.4M | -$60.5M | -$31.8M |
| Recovery of short-term investments at amortized cost | $92.3M | ||
| Interest received from investment at amortized cost | $701.0K | ||
| Addition of investments in associate | -$4.2M | ||
| Received investment income of financial assets at FVTPL | $1.0K | $62.0K | |
| Net cash flows (used in)/provided by investing activities | -$15.6M | $28.1M | -$11.0M |
| Proceeds from issuance of ordinary shares | $91.8M | ||
| Addition of bank borrowings | $37.7M | $44.7M | $50.2M |
| Bank borrowings interest paid | -$1.2M | -$1.9M | -$602.0K |
| Repayment of bank borrowings | -$39.7M | -$48.5M | -$24.1M |
| Exercise of share options | $152.0K | ||
| Payment for lease liabilities | -$633.0K | -$1.0M | -$1.1M |
| Net cash flows provided by/(used in) financing activities | -$3.8M | -$6.6M | $116.2M |
| NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS | -$52.8M | -$30.3M | $48.6M |
| Effect of foreign exchange rate changes, net | -$3.0K | -$257.0K | $100.0K |
Former names
- Adlai Nortye Ltd.Dec 21, 2022 to Aug 19, 20263
Recent filings
- Oct 1, 20264 PRIMARY DOCUMENT
- Sep 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Sep 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Sep 24, 20264 PRIMARY DOCUMENT
- Sep 18, 2026144
- Sep 15, 2026EFFECT
- Sep 11, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-3
- Sep 11, 2026S-8 POS REGISTRATION STATEMENT
- Sep 11, 2026S-8 POS REGISTRATION STATEMENT
- Sep 8, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Aug 26, 20266-K CURRENT REPORT
- Aug 26, 20264 PRIMARY DOCUMENT
- Aug 19, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Aug 14, 20266-K REPORT OF FOREIGN PRIVATE ISSUER
- Aug 14, 2026SCHEDULE 13G/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5